• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

EG 427

Monday, June 03, 2024
CP
Cell and Gene Therapy and Genome Editing
EG 427 develops a unique vector platform to deliver pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows either for long-term gene therapy, or all-in-one gene editing approaches. EG 427 is the second company to bring a non-replicating HSV-1 vector into clinical development with an IND filling with the FDA in early 2024. Our product, EG110A, addresses multiple severe bladder diseases (including NDO and OAB) by targeting selectively sensory neurons and has the potential to be a major improvement over existing therapies, resulting in better care for the patients and lower costs for the healthcare systems.
EG 427
Company Website: https://eg427.com
Lead Product in Development: EG110A for Neurogenic Detrusor Overactivity
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2 assets + platform available for new product development

Company HQ City

PARIS

Company HQ State

France

Company HQ Country

France

CEO/Top Company Official

Philippe Chambon

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS